Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
Sponsor: Chinese PLA General Hospital
This PHASE1/PHASE2 trial investigates T Cell Non-Hodgkin's Lymphoma and is currently ongoing. Chinese PLA General Hospital leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Nov 2022 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese PLA General Hospital
- Peking Union Medical College Hospital
- Peking University Cancer Hospital & Institute
- Peking University First Hospital
- Peking University Third Hospital
- Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .